IC50 Value & Target:
In Vitro: Treatment of 0.1 to 10μM Rb2 promoted the proliferation of MC3T3-E1 cells, improved alkaline phosphatase (ALP) expression, elevated calcium mineralization and mRNA expressions of Alp, Col1a1, osteocalcin (Ocn) and osteopontin (Opn) against oxidative damage induced by H2O2. Importantly, Rb2 reduced the expression levels of receptor activator of nuclear factor kappa-B ligand (RANKL) and IL-6 and inhibited the H2O2-induced production of ROS [1]. Ginsenoside-Rb2 showed the highest protective activity, although other dammarane-type and oleanolic acid-type ginsenosides also induced a significant protection against HVJ [2]. Rb2 (3~30 μM), perfused into an adrenal vein for 90 min, inhibited ACh (5.32 mM)-evoked CA secretory response in a dose- and time-dependent fashion. Rb2 (10 μM) also time-dependently inhibited the CA secretion evoked by DMPP (100 μM, a selective neuronal nicotinic receptor agonist) and high K(+) (56 mM, a direct membrane depolarizer) [3].
In Vivo: Multiple administrations of ginsenoside-Rb2 after the intravenous inoculation of B16-BL6 melanoma cells resulted in a significant inhibition of lung metastasis as compared with the untreated control [1].

 | | Dave Gao Sales Manager, Star Ocean Ginseng Professional Services Tel: +86 512 81662860 Mobile: +86 13776237441 Fax: +86 512 52856900 Email: sales@star-ocean-biotech.com, star-ocean@vip.163.com Address: High Tech Industrial Development Zone-Tongji Science and Technology Plaza, Changshu, Suzhou, China. |